Epilepsy Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Epilepsy Drugs Market is Segmented by Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, and Third Generation Anti-epileptics), Distribution Channel, and Geography

Epilepsy Drugs Market Snapshot

Epilepsy Drugs Market 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Europe
Largest Market: North America
CAGR: 3.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years and increasing cases of epilepsy across the globe.

Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. There is also rising awareness levels about epilepsy coupled with strategic alliances that are anticipated to stimulate the market growth. One of the organization Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.

Scope of the Report

As per the scope of this report, epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. The epilepsy drugs do not cure epilepsy but helps to control seizures. The drugs are classified into three major segments first generation, second generation, and third generation. 

By Drugs
First Generation Anti-epileptics
Second Generation Anti-epileptics
Third Generation Anti-epileptics
By Distribution Channel
Hospital Pharmacy
Pharmacy Stores
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Second Generation Anti-epileptics is the Segment by Drugs Expected to Hold a Large Market Share Over the Forecast Period

The second-generation Anti-epileptics drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.

Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018, one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

Epilepsy Drugs Market.png

To understand key trends, Download Sample Report

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer’s disease. About one percent of Americans have some form of epilepsy, and nearly four percent (1 in 26) will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson’s disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the epilepsy drug market.

Furthermore, there are various organizations making awareness about epilepsy in the United States. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.

Epilepsy Drugs Market.png

To understand geography trends, Download Sample Report

Competitive Landscape

The market studied is a consolidated market owing to the presence of few major market players. Therefore most of the key players are found focusing on the expansion of their businesses to increase their market share. Also, they are adopting certain strategies, such as new product development, mergers, and acquisitions.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in the New Drug Approvals over the Past Few Years

      2. 4.2.2 Increase in the Cases of Epilepsy

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated With the Drugs

      2. 4.3.2 Recent Patent Expiration of Major Brands

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drugs

      1. 5.1.1 First Generation Anti-epileptics

      2. 5.1.2 Second Generation Anti-epileptics

      3. 5.1.3 Third Generation Anti-epileptics

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacy

      2. 5.2.2 Pharmacy Stores

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 GlaxoSmithKline PLC

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Novartis AG

      5. 6.1.5 Pfizer, Inc.

      6. 6.1.6 Sanofi SA

      7. 6.1.7 Sunovion Pharmaceuticals Inc.

      8. 6.1.8 Takeda Pharmaceutical Company Limited

      9. 6.1.9 UCB S.A.,

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Epilepsy Drugs Market market is studied from 2018 - 2026.

The Epilepsy Drugs Market is growing at a CAGR of 3.2% over the next 5 years.

Europe is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson Health Care Systems Inc., Novartis AG, UCB S.A. are the major companies operating in Epilepsy Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!